We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $10.1B
1-Year Est. Return 42.88%
This Fund
S&P 500
This Quarter Est. Return
-27.19%
1 Year Est. Return
+42.88%
3 Year Est. Return
+92.52%
5 Year Est. Return
+113.84%
10 Year Est. Return
+608.05%
AUM
$7.34B
AUM Growth
-$3.86B
Cap. Flow
-$375M
Cap. Flow %
-5.12%
Top 10 Hldgs %
9.89%
Holding
1,223
New
86
Increased
388
Reduced
436
Closed
75

Top Buys

Rank Stock Value
1
ESE icon
ESCO Technologies
ESE
+$40.8M
2
HAE icon
Haemonetics
HAE
+$37.6M
3
ROG icon
Rogers Corp
ROG
+$26.2M
4
EVR icon
Evercore
EVR
+$25.5M
5
FARO
Faro Technologies
FARO
+$22M

Sector Composition

Rank Sector Weight
1 Industrials 25.72%
2 Technology 19.64%
3 Financials 14.17%
4 Consumer Discretionary 10.37%
5 Healthcare 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VALU icon
551
Value Line
VALU
$328M
$2.41M 0.03%
74,574
NOVT icon
552
Novanta
NOVT
$5.28B
$2.4M 0.03%
30,042
-10,000
-25% -$893K
CRAI icon
553
CRA International
CRAI
$1.17B
$2.39M 0.03%
71,589
CG icon
554
Carlyle Group
CG
$17.3B
$2.39M 0.03%
110,300
GD icon
555
General Dynamics
GD
$104B
$2.38M 0.03%
18,000
+1,000
+6% +$166K
EGRX
556
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$2.38M 0.03%
51,647
+1,661
+3% +$83.3K
AVD icon
557
American Vanguard Corp
AVD
$70.9M
$2.37M 0.03%
164,000
-61,000
-27% -$1.01M
PH icon
558
Parker-Hannifin
PH
$124B
$2.37M 0.03%
18,250
+5,750
+46% +$1.04M
AXSM icon
559
Axsome Therapeutics
AXSM
$10.7B
$2.36M 0.03%
40,100
-20,000
-33% -$1.63M
RTX icon
560
RTX Corp
RTX
$292B
$2.36M 0.03%
39,725
+8,739
+28% +$740K
MNTX
561
DELISTED
Manitex International, Inc.
MNTX
$2.36M 0.03%
570,488
+49,043
+9% +$257K
ODFL icon
562
Old Dominion Freight Line
ODFL
$43.8B
$2.34M 0.03%
35,604
-9,300
-21% -$618K
CSSE
563
DELISTED
Chicken Soup for the Soul Entertainment, Inc. Class A Common Stock
CSSE
$2.33M 0.03%
344,500
+10,000
+3% +$79K
SBR
564
Sabine Royalty Trust
SBR
$1.06B
$2.28M 0.03%
82,648
+23,100
+39% +$819K
PAAS icon
565
Pan American Silver
PAAS
$18.2B
$2.24M 0.03%
156,427
VCYT icon
566
Veracyte
VCYT
$3.59B
$2.22M 0.03%
91,150
KINS icon
567
Kingstone Companies
KINS
$292M
$2.21M 0.03%
433,177
-46,693
-10% -$330K
NDLS icon
568
Noodles & Co
NDLS
$110M
$2.19M 0.03%
58,096
+23,354
+67% +$1.25M
HLIT icon
569
Harmonic Inc
HLIT
$1.27B
$2.18M 0.03%
379,000
+31,500
+9% +$211K
LIQT icon
570
LiqTech
LIQT
$21.2M
$2.18M 0.03%
63,552
+35,200
+124% +$1.55M
KNL
571
DELISTED
Knoll, Inc.
KNL
$2.17M 0.03%
+210,278
New +$4.18M
JELD icon
572
JELD-WEN Holding
JELD
$129M
$2.16M 0.03%
+222,218
New +$4.43M
AEHR icon
573
Aehr Test Systems
AEHR
$2.91B
$2.16M 0.03%
1,293,900
+52,200
+4% +$101K
TBPH icon
574
Theravance Biopharma
TBPH
$874M
$2.16M 0.03%
93,300
BFYT
575
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$2.15M 0.03%
96,200
+37,000
+63% +$878K

Similar funds

Royce & Associates's Q1 2020 Portfolio in Review

As of Q1 2020, Royce & Associates held 1,223 positions worth $7.34B, down 34% from $11.2B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.

Royce & Associates withdrew a net $375M in Q1 2020, closing 75 positions and reducing 436 holdings. Its most notable exit was AVX Corporation, an estimated $71.1M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.

Against the trend, Royce & Associates opened a new position in ESCO Technologies worth $33.9M.

  • Royce & Associates's largest Q1 2020 buy was ESCO Technologies: 447,118 shares worth $33.9M.
  • Royce & Associates added most to Haemonetics in Q1 2020, an estimated $37.6M increase.
  • Royce & Associates's biggest Q1 2020 reduction was Virtu Financial, cutting an estimated $51M.
  • Royce & Associates fully exited AVX Corporation in Q1 2020, selling an estimated $71.1M.
  • Royce & Associates's ten largest holdings make up 9.9% of its $7.34B portfolio in Q1 2020.
  • Royce & Associates opened 86 new positions and closed 75 in Q1 2020.
  • Royce & Associates's portfolio value fell 34% quarter-over-quarter to $7.34B.

Based on Royce & Associates's 13F filing for Q1 2020, filed 12 May 2020.